PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Engel, Sinah, Luessi, Felix, Mueller, Aneka, Schopf, Rudolf E., Zipp, Frauke, Bittner, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940603/
https://www.ncbi.nlm.nih.gov/pubmed/31921355
http://dx.doi.org/10.1177/1756286419895155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940603/
https://www.ncbi.nlm.nih.gov/pubmed/31921355
http://dx.doi.org/10.1177/1756286419895155

Ejemplares similares